Click here to complete the interactive survey.
Once you submit your responses, you will be able to view all of your colleagues’ responses.
RJ, age 38 years, has a 15-year history of relapsing-remitting multiple sclerosis. She initially presented with highly-active MS and was started on beta-interferon-1a 44µg. She continued to have significant clinical disease activity and ongoing MRI lesions in both brain and spine. She was transitioned to fingolimod in 2012. Read More
A retrospective multicentre study (N=139) reports that a transition time <30 days when switching from natalizumab to an anti-CD20 agent is optimal for efficacy and safety (Bsteh et al. Eur J Neurol 2025;32:e16587). Mean age of patients at the time of switch was 38.8 years; median duration on natalizumab was 4.4 years. Read More
An analysis of the Swiss MS Cohort has found that routine monitoring of serum biomarkers can aid in predicting progression independent of relapse activity (PIRA) in patients during B cell-depleting therapy (Benkert et al. Ann Neurol 2025;97:104-115). Read More